Amgen

Open: 256.71 Close: 254.01 Change: -2.7

How to get informed about Amgen Stock quickly using an AI.

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, FTC, Therapeutics, acquisition, agreement, Federal, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

FTC filed lawsuit in May seeking to block Amgen takeover of Horizon Therapeutics over concerns it would allow Amgen to leverage its drug portfolio to stifle competition in the pharmaceutical industry. FTC said settlement would prevent “potential competitive harm

Today's News

Amgens $27.8 billion deal for Horizon Therapeutics clears key hurdle - wsj. amgen tipped to keep otezla market share in bms sotyktu fight. FTC filed lawsuit in May seeking to block Amgens takeover of Horizon Therapeutics over concerns it would allow Amgen to leverage its drug portfolio to stifle competition in the pharmaceutical industry. The agreement resolves a lawsuit the FTC filed in May. Amgen has reached a deal with the Federal Trade Commission that will enable the pharmaceutical company to complete its $28 billion acquisition of Horizon Therapeutics. The agreement “clears the path” for the final steps needed to close its acquisition. Amgen is prohibited from bundling an Amgen product with either Tepezza or Krystexxa, Horizons medications used to treat thyroid eye disease (TED) and chronic refractory gout (CRG) The proposed consent order resolves FTC and state charges that Amgens acquisition of Horizon is anticompetitive. Federal Trade Commission drops lawsuit to block Amgen-Horizon deal to acquire Horizon Therapeutics. FTC said settlement would prevent “potential competitive harm’ Amgen to present at the 2023 Wells Fargo Healthcare Conference at 9:30 a.30 a. Price Target $260.0 (2.36% upside) Analyst Consensus: Buy Stock. FTC suspends challenge to block Amgens $27.8 billion bid to acquire Horizon Therapeutics. FTC concerned Amgen will be able to bundle its products to a pharmacy benefit manager. Latest Amgen gives confidence to investors on $28B acquisition. Latest FTC pauses suit against Amgen on $27.8B acquisition on Friday. Amgen expects to complete the Horizon acquisition before 2023-end. Amgen and Horizon Therapeutics plc have entered into a consent order agreement with the Federal Trade Commission. This clears the path to take the final steps to close Amgens acquisition of Horizon. Amgen and Horizon Therapeutics have reached an agreement to acquire Horizon in December. The FTC settled on a proposed consent order with Amgen to address the potential competitive harm Amgen could bring. Federal Trade Commission (FTC) revealed an agreement with Amgen on a proposed consent order over its $27.8 billion deal to acquire Horizon Therapeutics. FTC, Amgen reach settlement on dispute over horizon therapeutics acquisition. Federal Trade Commission allows Amgen to continue $27.8 billion purchase of Horizon Therapeutics. FTC was concerned that Amgen would leverage its drugs to secure favorable insurance coverage terms for two Horizon drugs. Amgen, FTC Settle Over $27.8 billion takeover of Horizon Therapeutics. Truist Securities reiterates Amgen (AMGN) hold recommendation.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, FTC, Therapeutics, acquisition, agreement, Federal, and the most common words in the summary are: amgen, horizon, best, ftc, therapeutic, deal, drug, . One of the sentences in the summary was: FTC filed lawsuit in May seeking to block Amgen takeover of Horizon Therapeutics over concerns it would allow Amgen to leverage its drug portfolio to stifle competition in the pharmaceutical industry. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #horizon #best #ftc #therapeutic #deal #drug.